Shi B, Suo R, Song W, Zhang H, Liu D, Dai X
BMC Cardiovasc Disord. 2024; 24(1):654.
PMID: 39550544
PMC: 11568604.
DOI: 10.1186/s12872-024-04306-y.
Mu F, Wang M, Zeng X, Liu L, Wang F
Reprod Sci. 2023; 31(3):746-753.
PMID: 37932551
PMC: 10912122.
DOI: 10.1007/s43032-023-01388-5.
Caraiola S, Voicu L, Jurcut C, Dima A, Baicus C, Baicus A
Biomedicines. 2023; 11(8).
PMID: 37626689
PMC: 10452164.
DOI: 10.3390/biomedicines11082192.
Mahmud S, Bullock D, Correll C, Hobday P, Riskalla M, Vehe R
Pediatr Rheumatol Online J. 2022; 20(1):70.
PMID: 35987646
PMC: 9392300.
DOI: 10.1186/s12969-022-00732-4.
Eide J, Wu J, Stevens W, Bai J, Hou S, Huang J
Clin Exp Allergy. 2022; 52(8):954-964.
PMID: 35253284
PMC: 9339491.
DOI: 10.1111/cea.14120.
Levels and avidities of antiphosphatidylethanolamine antibodies in patients with thrombotic events and immunologically-mediated diseases.
Kuchar O, Petrackova M, Kalousova M, Noskova L, Zima T, Fialova L
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2022; 167(3):254-262.
PMID: 35147138
DOI: 10.5507/bp.2022.003.
Antiphospholipid Antibody Assays in 2021: Looking for a Predictive Value in Addition to a Diagnostic One.
Meroni P, Borghi M
Front Immunol. 2021; 12:726820.
PMID: 34621272
PMC: 8490700.
DOI: 10.3389/fimmu.2021.726820.
Metabolites Associated With the Risk of Incident Venous Thromboembolism: A Metabolomic Analysis.
Jiang X, Zeleznik O, Lindstrom S, Lasky-Su J, Hagan K, Clish C
J Am Heart Assoc. 2018; 7(22):e010317.
PMID: 30571496
PMC: 6404443.
DOI: 10.1161/JAHA.118.010317.
Early endosome as a pathogenic target for antiphosphatidylethanolamine antibodies.
Hou S, Folsch H, Ke K, Cook Mills J, Ramsey-Goldman R, Zhao M
Proc Natl Acad Sci U S A. 2017; 114(52):13798-13803.
PMID: 29229837
PMC: 5748199.
DOI: 10.1073/pnas.1714027115.
Clinical Risk Assessment in the Antiphospholipid Syndrome: Current Landscape and Emerging Biomarkers.
Chaturvedi S, McCrae K
Curr Rheumatol Rep. 2017; 19(7):43.
PMID: 28711993
DOI: 10.1007/s11926-017-0668-2.
The outcome of ELISA for antiphosphatidylethanolamine antibodies is dependent on the composition of phosphatidylethanolamine.
Hou S, Harper P, Bardin N, Zhao M
J Immunol Methods. 2016; 440:27-34.
PMID: 27784626
PMC: 5186409.
DOI: 10.1016/j.jim.2016.10.005.
Thrombotic risk assessment in antiphospholipid syndrome: the role of new antibody specificities and thrombin generation assay.
Sciascia S, Baldovino S, Schreiber K, Solfietti L, Radin M, Cuadrado M
Clin Mol Allergy. 2016; 14:6.
PMID: 27429595
PMC: 4947367.
DOI: 10.1186/s12948-016-0043-2.
Influence of Phosphatidylethanolamine Concentration and Composition on the Detection of Antiphosphatidylethanolamine Antibodies by ELISA.
Ke K, Strango Z, Harper P, Zhao M
J Clin Lab Anal. 2016; 30(5):689-96.
PMID: 27061173
PMC: 5042802.
DOI: 10.1002/jcla.21923.
Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers.
Meroni P, Chighizola C, Rovelli F, Gerosa M
Arthritis Res Ther. 2014; 16(2):209.
PMID: 25166960
PMC: 4060447.
DOI: 10.1186/ar4549.
Antiphospholipid antibodies in localized scleroderma: the potential role of screening tests for the detection of antiphospholipid syndrome.
Lis-Swiety A, Brzezinska-Wcislo L, Arasiewicz H, Bergler-Czop B
Postepy Dermatol Alergol. 2014; 31(2):65-70.
PMID: 25097470
PMC: 4112255.
DOI: 10.5114/pdia.2014.40978.
Discontinuation of anticoagulation or antiaggregation treatment may be safe in patients with primary antiphospholipid syndrome when antiphospholipid antibodies became persistently negative.
Coloma Bazan E, Donate Lopez C, Moreno Lozano P, Cervera R, Espinosa G
Immunol Res. 2013; 56(2-3):358-61.
PMID: 23568055
DOI: 10.1007/s12026-013-8407-x.
Cerebral venous thrombosis revealing primary sjögren syndrome: report of 2 cases.
Mercurio A, Altieri M, Saraceni V, Paolucci T, Lenzi G
Case Rep Med. 2013; 2013:747431.
PMID: 23424596
PMC: 3570939.
DOI: 10.1155/2013/747431.
Presence of antiphospholipid antibody is a risk factor in thrombotic events in patients with antiphospholipid syndrome or relevant diseases.
Habe K, Wada H, Matsumoto T, Ohishi K, Ikejiri M, Matsubara K
Int J Hematol. 2013; 97(3):345-50.
PMID: 23378183
DOI: 10.1007/s12185-013-1277-0.